Following a review by the European Medicines Agency (EMA), there is no evidence linking GLP-1 drugs like Ozempic (Semaglutide) to thyroid cancer. However, caution is advised, and patients are urged to report symptoms such as shortness of breath, trouble swallowing, neck lumps, or hoarseness to their healthcare provider.